Skip to main navigation Skip to search Skip to main content

Effect of metformin on epicardial adipose tissue in patients with coronary artery disease without diabetes: A cardiac MRI substudy of the MET-remodel trial

Research output: Contribution to journalShort surveypeer-review

Abstract

Epicardial adipose tissue (EAT) is a risk factor implicated in the pathogenesis and prognosis of cardiovascular disease. Metformin has been shown to regress EAT in animal models and observational studies. In this study, we report that metformin has no effect on EAT in patients with coronary artery disease without diabetes.

Original languageEnglish
Article number100349
Number of pages2
JournalObesity Medicine
Volume24
Early online date13 May 2021
DOIs
Publication statusPublished - Jun 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cardiac MRI
  • Coronary artery disease
  • Epicardial adipose tissue
  • Metformin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Public Health, Environmental and Occupational Health

Fingerprint

Dive into the research topics of 'Effect of metformin on epicardial adipose tissue in patients with coronary artery disease without diabetes: A cardiac MRI substudy of the MET-remodel trial'. Together they form a unique fingerprint.

Cite this